Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 28.00 as of 2026-10-06T22:00:53.643Z.
Consensus retrieved: 2026-10-06T08:30:56.626Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:00:53.643Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2f91371c98601992cb4f806dac5d33f8bd3579fef610bc8da11ff7230148e7c
Forward PE Ratio (28.00) = Dated Quote Price ($7.49) / Consensus Forward EPS ($0.27)
FORWARD PE RATIO
28.00
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+41.77%
vs the sector median at left
Agenus Inc.
Market Cap
$311.90M
Forward PE Ratio
28.00
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Agenus Inc. (AGEN) | $311.90M | 28.00 |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 184.21 |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A |
| CapsoVision, Inc. (CV)vs › | $324.76M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A |
Trailing P/E
2.8
reported TTM EPS
Forward P/E
28.0
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.27 implies -89.8% EPS decline vs the reported trailing $2.65.
At the dated quote price of $7.49, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.27 | $-0.81 – $0.88 | 2 | 28.0x |
| 2027-12-31 | $-0.60 | $-1.13 – $-0.14 | 2 | n/m |
| 2028-12-31 | $-0.58 | $-0.85 – $-0.31 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
